4.18
Precedente Chiudi:
$4.175
Aprire:
$4.15
Volume 24 ore:
27,410
Relative Volume:
0.04
Capitalizzazione di mercato:
$92.28M
Reddito:
-
Utile/perdita netta:
$-94.11M
Rapporto P/E:
-0.6955
EPS:
-6.01
Flusso di cassa netto:
$-86.06M
1 W Prestazione:
+0.95%
1M Prestazione:
-3.05%
6M Prestazione:
+71.86%
1 anno Prestazione:
-26.91%
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ADVM
Adverum Biotechnologies Inc
|
4.18 | 92.06M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.19 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.07 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.05 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.87 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.12 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Sells 51,961 Shares - MarketBeat
Adverum Biotechnologies Releases Promising Phase 2 Trial Data - TipRanks
Adverum Biotechnologies, Inc. Announces Two-Year Data from LUNA Phase 2 Trial - TradingView
How Adverum Biotechnologies Inc. (AVU0) stock reacts to stronger dollarJuly 2025 Highlights & Growth Oriented Trade Recommendations - Newser
Why Adverum Biotechnologies Inc. (AVU0) stock trades below fair valueMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Is Adverum Biotechnologies Inc. (AVU0) stock resilient in recession scenariosQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Is Adverum Biotechnologies Inc. (AVU0) stock undervalued by metricsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Published on: 2025-12-02 05:06:35 - Newser
What technical patterns form on Adverum Biotechnologies Inc. (AVU0) stock charts - Newser
Will Adverum Biotechnologies Inc. (AVU0) stock return to pre crash levelsMarket Growth Review & Consistent Profit Trading Strategies - Newser
Why retail traders accumulate Adverum Biotechnologies Inc. (AVU0) stock2025 Volume Leaders & Fast Gain Swing Trade Alerts - Newser
How Adverum Biotechnologies Inc. (AVU0) stock performs in volatility spikesQuarterly Market Review & Precise Trade Entry Recommendations - Newser
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns - Investing.com Canada
Adverum reminds stockholders to tender their shares into the offer by Lilly - marketscreener.com
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnolo - GuruFocus
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns By Investing.com - Investing.com South Africa
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biote - The National Law Review
What analysts say about Adverum Biotechnologies Inc stockSector Performance Review & Free Rapid Portfolio Appreciation - earlytimes.in
Adverum Biotechnologies Faces Lease Termination Notice - TipRanks
Adverum Biotechnologies IncARE-NC Region No. 21 LLC terminates certain lease agreement with Adverum BiotechnologiesSEC filing - MarketScreener
[8-K] Adverum Biotechnologies, Inc. Reports Material Event | ADVM SEC FilingForm 8-K - Stock Titan
Lilly strengthens gene therapy portfolio with MeiraGTx and Adverum deals - Drug Discovery News
Chart overlay techniques for tracking Adverum Biotechnologies Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Is Adverum Biotechnologies Inc. stock cheap compared to fundamentals2025 Retail Activity & Weekly High Momentum Picks - newser.com
Why Adverum Biotechnologies Inc. stock remains on watchlistsJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Adverum Biotechnologies (ADVM) Price Target Decreased by 11.61% to 10.10 - MSN
Will Adverum Biotechnologies Inc. stock maintain growth storyMarket Growth Report & Safe Swing Trade Setups - newser.com
Has Adverum Biotechnologies Inc. found a price floor2025 Risk Factors & Low Risk High Reward Ideas - newser.com
Volume spikes in Adverum Biotechnologies Inc. stock – what they mean2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Will Adverum Biotechnologies Inc. (AVU0) stock benefit from mergersJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum - sharewise.com
Published on: 2025-11-19 05:22:39 - newser.com
Will Adverum Biotechnologies Inc. stock deliver consistent dividends2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Published on: 2025-11-18 23:52:15 - newser.com
Why analysts maintain buy rating on Adverum Biotechnologies Inc. (AVU0) stockWatch List & Target Return Focused Picks - newser.com
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adverum Biotechnologies Inc Azioni (ADVM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Dec 03 '25 |
Sale |
4.17 |
222,925 |
929,597 |
2,428,640 |
| Leonard Braden Michael | 10% Owner |
Dec 02 '25 |
Sale |
4.20 |
51,961 |
218,236 |
2,705,565 |
| Soparkar Peter | CHIEF OPERATING OFFICER |
May 15 '25 |
Sale |
2.00 |
2,960 |
5,920 |
39,154 |
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
| Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
| Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
| Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):